High-Ranking Meddling Behind Sarepta Duchenne Drug Delay?
Executive Summary
Involvements of senior FDA officials may be the reason the agency put off its much-anticipated decision last week on Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy drug eteplirsen, analysts said.